Differential metal content and gene expression in rat left ventricular hypertrophy due to hypertension and hyperactivity

Journal of Trace Elements in Medicine and Biology

Volumn 28, Issue 3, 2014, Pages 311-316

  Subramanian, Meenakumari ^a   Hunt, Adam L ^a   Petrucci, Giuseppe A ^a   Chen, Zengyi ^b   Hendley, Edith D ^a   Palmer, Bradley M ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium; Cardiac hypertrophy; Copper; Monoamine oxidase; Zinc

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CALCIUM; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C OXIDASE; DOPAMINE BETA MONOOXYGENASE; IRON; MAGNESIUM; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; MUSCLE PROTEIN; MYOGLOBIN; PHOSPHOLEMMAN; POTASSIUM; PROTEIN LYSINE 6 OXIDASE; UNCLASSIFIED DRUG; ZINC; AMINE OXIDASE (FLAVIN CONTAINING);

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BALANCE; CALCIUM OVERLOAD; COX3 GENE; CROSS BREEDING; DBH GENE; FXYD1 GENE; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MITOCHONDRION; HYPERACTIVITY; HYPERTENSION; INBREEDING; LOX GENE; LOXL1 GENE; LOXL2 GENE; MAOA GENE; MAOB GENE; MB GENE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SOD1 GENE; SPONTANEOUSLY HYPERTENSIVE RAT; TISSUE LEVEL; TYR GENE; WISTAR KYOTO RAT; ANIMAL; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIUM; COPPER; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MONOAMINE OXIDASE; RATS; RATS, SPRAGUE-DAWLEY; ZINC;

EID: 84903648776     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.02.002     Document Type: Article

References (30)

1. Adams M.A., Bobik A., Korner P.I. Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. Hypertension 1989, 14:191-202.
2. Cutilletta A.F., Benjamin M., Culpepper W.S., Oparil S. Myocardial hypertrophy and ventricular performance in the absence of hypertension in spontaneously hypertensive rats. Journal of Molecular and Cellular Cardiology 1978, 10:689-693.
3. Cutilletta A.F., Erinoff L., Heller A., Low J., Oparil S. Development of left ventricular hypertrophy in young spontaneously hypertensive rats after peripheral sympathectomy. Circulation Research 1977, 40:428-434.
4. Whitehorn D., Atwater D.G., Low W.C., Gellis J.E., Hendley E.D. Independence of blood pressure and locomotor hyperactivity in normotensive and genetically hypertensive rat. Behavioral and Neural Biology 1983, 37:357-361.
5. Hendley E.D., Wessel D.J., Van Houten J. Inbreeding of Wistar-Kyoto rat strain with hyperactivity but without hypertension. Behavioral and Neural Biology 1986, 45:1-16.
6. Hendley E.D., Ohlsson W.G. Two new inbred rat strains derived from SHR: WKHA, hyperactive, and WKHT, hypertensive, rats. The American Journal of Physiology 1991, 261:H583-H589.
7. Deschepper C.F., Masciotra S., Zahabi A., Boutin-Ganache I., Picard S., Reudelhuber T.L. Functional alterations of the Nppa promoter are linked to cardiac ventricular hypertrophy in WKY/WKHA rat crosses. Circulation Research 2001, 88:223-228.
8. Palmer B.M., Chen Z., Lachapelle R.R., Hendley E.D., LeWinter M.M. Cardiomyocyte function associated with hyperactivity and/or hypertension in genetic models of LV hypertrophy. American Journal of Physiology Heart and Circulatory Physiology 2006, 290:H463-H473.
9. Bing O.H., Conrad C.H., Boluyt M.O., Robinson K.G., Brooks W.W. Studies of prevention, treatment and mechanisms of heart failure in the aging spontaneously hypertensive rat. Heart Failure Review 2002, 7:71-88.
10. Bush E., Fielitz J., Melvin L., Martinez-Arnold M., McKinsey T.A., Plichta R., et al. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:2870-2875.
11. Chien K.R. Meeting Koch's postulates for calcium signaling in cardiac hypertrophy. The Journal of Clinical Investigation 2000, 105:1339-1342.
12. Yi T., Vick J.S., Vecchio M.J., Begin K.J., Bell S.P., Delay R.J., et al. Identifying cellular mechanisms of zinc-induced relaxation in isolated cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology 2013, 305:H706-H715.
13. Kay A.R. Detecting and minimizing zinc contamination in physiological solutions. BMC Physiology 2004, 4:4.
14. Williams J.L., Hathaway C.A., Kloster K.L., Layne B.H. Low power, type II errors, and other statistical problems in recent cardiovascular research. The American Journal of Physiology 1997, 273:H487-H493.
15. Hendley E.D., Fan X.M. Regional differences in brain norepinephrine and dopamine uptake kinetics in inbred rat strains with hypertension and/or hyperactivity. Brain Research 1992, 586:44-52.
16. Peruzzi D., Hendley E.D., Forehand C.J. Hypertrophy of stellate ganglion cells in hypertensive, but not hyperactive, rats. The American Journal of Physiology 1991, 261:R979-R984.
17. Balsa E., Marco R., Perales-Clemente E., Szklarczyk R., Calvo E., Landazuri M.O., et al. NDUFA4 is a subunit of complex IV of the mammalian electron transport chain. Cell Metabolism 2012, 16:378-386.
18. Fukai T., Folz R.J., Landmesser U., Harrison D.G. Extracellular superoxide dismutase and cardiovascular disease. Cardiovascular Research 2002, 55:239-249.
19. Cheung J.Y., Zhang X.Q., Song J., Gao E., Chan T.O., Rabinowitz J.E., et al. Coordinated regulation of cardiac Na(+)/Ca (2+) exchanger and Na (+)-K (+)-ATPase by phospholemman (FXYD1). Advances in Experimental Medicine and Biology 2013, 961:175-190.
20. Hendley E.D. WKHA rats with genetic hyperactivity and hyperreactivity to stress: a review. Neuroscience and Biobehavioral Reviews 2000, 24:41-44.
21. 2+ current in rat ventricular cardiomyocytes: consequences in cardiac diseases. Pflugers Archiv 2012, 464:459-470.
22. Cooper G.J., Young A.A., Gamble G.D., Occleshaw C.J., Dissanayake A.M., Cowan B.R., et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia 2009, 52:715-722.
23. Vidal M., Wieland T., Lohse M.J., Lorenz K. Beta-adrenergic receptor stimulation causes cardiac hypertrophy via a Gbetagamma/Erk-dependent pathway. Cardiovascular Research 2012, 96:255-264.
24. Turski M.L., Brady D.C., Kim H.J., Kim B.E., Nose Y., Counter C.M., et al. A novel role for copper in Ras/mitogen-activated protein kinase signaling. Molecular and Cellular Biology 2012, 32:1284-1295.
25. Kliment C.R., Suliman H.B., Tobolewski J.M., Reynolds C.M., Day B.J., Zhu X., et al. Extracellular superoxide dismutase regulates cardiac function and fibrosis. Journal of Molecular and Cellular Cardiology 2009, 47:730-742.
26. Deschepper C.F., Picard S., Thibault G., Touyz R., Rouleau J.L. Characterization of myocardium, isolated cardiomyocytes, and blood pressure in WKHA and WKY rats. American Journal of Physiology Heart and Circulatory Physiology 2002, 282:H149-H155.
27. Kaludercic N., Carpi A., Menabo R., Di Lisa F., Paolocci N. Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochimica et Biophysica Acta 2011, 1813:1323-1332.
28. Bianchi P., Pimentel D.R., Murphy M.P., Colucci W.S., Parini A. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2005, 19:641-643.
29. Kaludercic N., Takimoto E., Nagayama T., Feng N., Lai E.W., Bedja D., et al. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circulation Research 2010, 106:193-202.
30. Lairez O., Calise D., Bianchi P., Ordener C., Spreux-Varoquaux O., Guilbeau-Frugier C., et al. Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload. Journal of Molecular and Cellular Cardiology 2009, 46:587-595.